Published in Nature on April 01, 2010
Natively inhibited Trypanosoma brucei cathepsin B structure determined by using an X-ray laser. Science (2012) 5.83
ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol (2011) 3.38
Modulation of the Surface Proteome through Multiple Ubiquitylation Pathways in African Trypanosomes. PLoS Pathog (2015) 2.07
Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. Nat Chem (2013) 1.95
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis (2011) 1.66
ALDH2 mediates 5-nitrofuran activity in multiple species. Chem Biol (2012) 1.48
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
Global analysis of protein N-myristoylation and exploration of N-myristoyltransferase as a drug target in the neglected human pathogen Leishmania donovani. Chem Biol (2015) 1.47
The chemical toolbox for monitoring protein fatty acylation and prenylation. Nat Chem Biol (2010) 1.42
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol (2017) 1.38
Targeting protein lipidation in disease. Trends Mol Med (2012) 1.37
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem (2011) 1.33
Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol (2010) 1.33
Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr Top Med Chem (2011) 1.27
Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1. PLoS Negl Trop Dis (2010) 1.20
A fluorescence-based assay for N-myristoyltransferase activity. Anal Biochem (2011) 1.20
Global profiling of co- and post-translationally N-myristoylated proteomes in human cells. Nat Commun (2014) 1.19
Lipid metabolism in Trypanosoma brucei. Mol Biochem Parasitol (2010) 1.16
A tetracycline-repressible transactivator system to study essential genes in malaria parasites. Cell Host Microbe (2012) 1.16
Exploring protein lipidation with chemical biology. Chem Rev (2011) 1.15
The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis (2011) 1.14
Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets. J Infect Dis (2012) 1.12
Global profiling of protein lipidation using chemical proteomic technologies. Curr Opin Chem Biol (2014) 1.10
Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite. Future Med Chem (2011) 1.10
Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. J Med Chem (2012) 1.09
Drug discovery for neglected diseases: molecular target-based and phenotypic approaches. J Med Chem (2013) 1.05
Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery. J Med Chem (2012) 1.03
Acylation-dependent export of Trypanosoma cruzi phosphoinositide-specific phospholipase C to the outer surface of amastigotes. J Biol Chem (2010) 0.98
Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors. J Med Chem (2014) 0.95
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP). J Med Chem (2014) 0.95
25 years of African trypanosome research: From description to molecular dissection and new drug discovery. Mol Biochem Parasitol (2015) 0.93
A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl Trop Dis (2012) 0.92
Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther (2014) 0.92
Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors. IUCrJ (2014) 0.90
A role for the vesicle-associated tubulin binding protein ARL6 (BBS3) in flagellum extension in Trypanosoma brucei. Biochim Biophys Acta (2012) 0.89
Acylation in trypanosomatids: an essential process and potential drug target. Trends Parasitol (2014) 0.88
Antiparasitic chemotherapy: from genomes to mechanisms. Annu Rev Pharmacol Toxicol (2013) 0.88
Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites. Org Biomol Chem (2014) 0.87
Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase. Biochem J (2014) 0.87
Myristoylome profiling reveals a concerted mechanism of ARF GTPase deacylation by the bacterial protease IpaJ. Mol Cell (2015) 0.86
Innovation in academic chemical screening: filling the gaps in chemical biology. Curr Opin Chem Biol (2013) 0.85
Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. Open Biol (2013) 0.85
Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl Trop Dis (2011) 0.85
A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes. PLoS Negl Trop Dis (2014) 0.84
Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. Parasitology (2013) 0.82
Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes. PLoS Negl Trop Dis (2014) 0.82
Fatty acylation of proteins: The long and the short of it. Prog Lipid Res (2016) 0.81
Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis. PLoS Pathog (2015) 0.81
Drug target identification using a trypanosome overexpression library. Antimicrob Agents Chemother (2014) 0.80
Drug Discovery in Academia- the third way? Expert Opin Drug Discov (2010) 0.80
Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries. J Chem Inf Model (2013) 0.80
Cellular FRET-Biosensors to Detect Membrane Targeting Inhibitors of N-Myristoylated Proteins. PLoS One (2013) 0.79
Prophylactic antiparasitic transgenesis for human parasitic disease? Mol Ther (2010) 0.79
Infectious disease: Genomics decodes drug action. Nature (2012) 0.79
Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei. J Med Chem (2015) 0.78
In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis. Antimicrob Agents Chemother (2012) 0.78
N-myristoyltransferase is a cell wall target in Aspergillus fumigatus. ACS Chem Biol (2015) 0.78
Trypanocidal activity of marine natural products. Mar Drugs (2013) 0.78
Inhibition of isoleucyl-tRNA synthetase as a potential treatment for human African Trypanosomiasis. J Biol Chem (2013) 0.78
Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase. PLoS Negl Trop Dis (2016) 0.78
Trypanosoma brucei brucei: endocytic recycling is important for mouse infectivity. Exp Parasitol (2011) 0.77
Systems Analysis of Protein Fatty Acylation in Herpes Simplex Virus-Infected Cells Using Chemical Proteomics. Chem Biol (2015) 0.77
Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei. ACS Infect Dis (2016) 0.77
Structure and Functional Diversity of GCN5-Related N-Acetyltransferases (GNAT). Int J Mol Sci (2016) 0.77
A new, robust, and nonradioactive approach for exploring N-myristoylation. J Lipid Res (2012) 0.77
Wnt Lipidation and Modifiers in Intestinal Carcinogenesis and Cancer. Cancers (Basel) (2016) 0.77
N-myristoyltransferase in the leukocytic development processes. Cell Tissue Res (2011) 0.76
Analyzing a Potential Drug Target N-Myristoyltransferase of Plasmodium falciparum Through In Silico Approaches. J Glob Infect Dis (2012) 0.76
TFPP: an SVM-based tool for recognizing flagellar proteins in Trypanosoma brucei. PLoS One (2013) 0.76
Chemical genomics for studying parasite gene function and interaction. Trends Parasitol (2013) 0.76
Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase. Medchemcomm (2015) 0.76
Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem (2015) 0.76
The N-myristoylome of Trypanosoma cruzi. Sci Rep (2016) 0.75
Identification of Human N-Myristoylated Proteins from Human Complementary DNA Resources by Cell-Free and Cellular Metabolic Labeling Analyses. PLoS One (2015) 0.75
N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells. ACS Chem Biol (2016) 0.75
Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Negl Trop Dis (2016) 0.75
Multiple chemical scaffolds inhibit a promising Leishmania drug target. IUCrJ (2014) 0.75
Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferase. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. Acta Crystallogr F Struct Biol Commun (2015) 0.75
An evaluation of Minor Groove Binders as anti-Trypanosoma brucei brucei therapeutics. Eur J Med Chem (2016) 0.75
Drug discovery: Fat-free proteins kill parasites. Nature (2010) 0.75
Dynamic protein S-palmitoylation mediates parasite life cycle progression and diverse mechanisms of virulence. Crit Rev Biochem Mol Biol (2017) 0.75
Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. Medchemcomm (2016) 0.75
Fluorescent imaging of protein myristoylation during cellular differentiation and development. J Lipid Res (2017) 0.75
Cell Cycle Inhibition To Treat Sleeping Sickness. MBio (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop (1997) 4.73
Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol (2006) 4.11
Glycosyl-sn-1,2-dimyristylphosphatidylinositol is covalently linked to Trypanosoma brucei variant surface glycoprotein. J Biol Chem (1985) 3.64
The biology and enzymology of protein N-myristoylation. J Biol Chem (2001) 3.14
Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes. Cell (2007) 2.84
N-terminal N-myristoylation of proteins: prediction of substrate proteins from amino acid sequence. J Mol Biol (2002) 2.18
Clathrin-mediated endocytosis is essential in Trypanosoma brucei. EMBO J (2003) 2.11
Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem (2002) 2.08
Myristylation of the membrane form of a Trypanosoma brucei variant surface glycoprotein. J Biol Chem (1984) 2.07
Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem (2008) 1.94
Acylation-dependent protein export in Leishmania. J Biol Chem (2000) 1.77
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. Acta Trop (2008) 1.64
Endocytosis, membrane recycling and sorting of GPI-anchored proteins: Trypanosoma brucei as a model system. Mol Microbiol (2004) 1.51
CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol Biochem Parasitol (2001) 1.49
Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol Microbiol (2008) 1.33
N-myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem (2008) 1.33
Functional analysis of TbARL1, an N-myristoylated Golgi protein essential for viability in bloodstream trypanosomes. J Cell Sci (2005) 1.30
Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochem J (2006) 1.30
A second mammalian N-myristoyltransferase. J Biol Chem (1998) 1.28
Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol Biochem Parasitol (2009) 1.28
Trypanosoma brucei ARF1 plays a central role in endocytosis and golgi-lysosome trafficking. Mol Biol Cell (2006) 1.26
An analog of myristic acid with selective toxicity for African trypanosomes. Science (1991) 1.22
Kinetoplastid PPEF phosphatases: dual acylated proteins expressed in the endomembrane system of Leishmania. Mol Biochem Parasitol (2006) 1.21
Potential role of N-myristoyltransferase in cancer. Prog Lipid Res (2006) 1.15
Both of the Rab5 subfamily small GTPases of Trypanosoma brucei are essential and required for endocytosis. Mol Biochem Parasitol (2004) 1.15
Structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoylCoA and peptide provide insights about substrate recognition and catalysis. Biochemistry (2001) 1.15
Antifungals targeted to protein modification: focus on protein N-myristoyltransferase. Expert Opin Investig Drugs (2002) 1.12
The structure of myristoyl-CoA:protein N-myristoyltransferase. Biochim Biophys Acta (1999) 1.08
Structural insights into membrane targeting by the flagellar calcium-binding protein (FCaBP), a myristoylated and palmitoylated calcium sensor in Trypanosoma cruzi. J Biol Chem (2008) 1.02
S-myristoylation of a glycosylphosphatidylinositol-specific phospholipase C in Trypanosoma brucei. J Biol Chem (1999) 1.02
Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase. ChemMedChem (2009) 0.98
Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins. J Virol (2005) 0.92
Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design. J Comput Aided Mol Des (2009) 0.88
Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med (2013) 20.70
The genome of the African trypanosome Trypanosoma brucei. Science (2005) 11.48
The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 8.64
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10
Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet (2007) 4.58
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Condition-dependent transcriptome reveals high-level regulatory architecture in Bacillus subtilis. Science (2012) 4.41
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet (2010) 4.01
Protein production and purification. Nat Methods (2008) 3.97
TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res (2009) 3.79
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol (2002) 2.92
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res (2010) 2.75
Phosphorylation of immunity-related GTPases by a Toxoplasma gondii-secreted kinase promotes macrophage survival and virulence. Cell Host Microbe (2010) 2.57
Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol (2006) 2.39
Global network reorganization during dynamic adaptations of Bacillus subtilis metabolism. Science (2012) 2.38
Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature (2004) 2.36
MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell (2005) 2.29
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol (2008) 2.22
The non-catalytic chitin-binding protein CBP21 from Serratia marcescens is essential for chitin degradation. J Biol Chem (2005) 2.18
Conserved arginine residues implicated in ATP hydrolysis, nucleotide-sensing, and inter-subunit interactions in AAA and AAA+ ATPases. J Struct Biol (2004) 2.15
Pound-wise but penny-foolish: How well do micromolecules fare in macromolecular refinement? Structure (2003) 2.14
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem (2002) 2.08
A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol (2013) 1.98
Target assessment for antiparasitic drug discovery. Trends Parasitol (2007) 1.96
Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci U S A (2010) 1.96
Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. J Biol Chem (2005) 1.95
High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J (2002) 1.93
Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res (2008) 1.93
Structures of apicomplexan calcium-dependent protein kinases reveal mechanism of activation by calcium. Nat Struct Mol Biol (2010) 1.91
Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res (2011) 1.90
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem (2004) 1.86
GeneDB--an annotation database for pathogens. Nucleic Acids Res (2011) 1.82
Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. Chem Biol (2005) 1.80
Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J (2004) 1.77
Crystal structure and binding properties of the Serratia marcescens chitin-binding protein CBP21. J Biol Chem (2004) 1.76
Pseudokinases-remnants of evolution or key allosteric regulators? Curr Opin Struct Biol (2010) 1.76
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med (2003) 1.75
Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J Biol Chem (2002) 1.71
Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. Chem Biol (2008) 1.71
Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab (2010) 1.67
IUPHAR-DB: updated database content and new features. Nucleic Acids Res (2012) 1.66
Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence. J Biol Chem (2004) 1.66
Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci (2004) 1.65
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
Structural insights into mechanism and specificity of O-GlcNAc transferase. EMBO J (2008) 1.63
Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol (2008) 1.63
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev (2013) 1.60
Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. EMBO J (2006) 1.57
The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African sleeping sickness. Mol Cell Proteomics (2009) 1.56
p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut (2006) 1.56
The structure of CodY, a GTP- and isoleucine-responsive regulator of stationary phase and virulence in gram-positive bacteria. J Biol Chem (2006) 1.54
Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J Biol Chem (2003) 1.52
Comparative SILAC proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages. PLoS One (2012) 1.50
Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii. EMBO J (2009) 1.50
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother (2010) 1.49
Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei. Proc Natl Acad Sci U S A (2002) 1.49
ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol (2009) 1.47
Safety, feasibility, and outcomes of induced hypothermia therapy following in-hospital cardiac arrest-evaluation of a large prospective registry*. Crit Care Med (2014) 1.45
Sphingolipid-free Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol Microbiol (2004) 1.45
BslA is a self-assembling bacterial hydrophobin that coats the Bacillus subtilis biofilm. Proc Natl Acad Sci U S A (2013) 1.44
Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology (2012) 1.44
Decoys for docking. J Med Chem (2005) 1.43
Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations. Open Biol (2011) 1.42
Retracted Skeletal muscle-specific CPT1 deficiency elevates lipotoxic intermediates but preserves insulin sensitivity. J Diabetes Res (2013) 1.41
Crystal structure of MO25 alpha in complex with the C terminus of the pseudo kinase STE20-related adaptor. Nat Struct Mol Biol (2004) 1.41
Crystal structure of dihydrodipicolinate synthase (BA3935) from Bacillus anthracis at 1.94 A resolution. Proteins (2006) 1.40
Lipid spirals in Bacillus subtilis and their role in cell division. Mol Microbiol (2008) 1.40
The protozoan inositol phosphorylceramide synthase: a novel drug target that defines a new class of sphingolipid synthase. J Biol Chem (2006) 1.39
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem (2009) 1.39
Sugar nucleotide pools of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major. Eukaryot Cell (2007) 1.37
Stress transfer of a Kevlar 49 fiber pullout test studied by micro-Raman spectroscopy. Appl Spectrosc (2013) 1.36
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Nucleosomes can invade DNA territories occupied by their neighbors. Nat Struct Mol Biol (2009) 1.34
Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol Cancer Res (2011) 1.34
Protein engineering 20 years on. Nat Rev Mol Cell Biol (2002) 1.34